Journal
CLINICAL INFECTIOUS DISEASES
Volume 60, Issue 12, Pages 1860-1863Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/civ155
Keywords
HIV/AIDS; tuberculosis; efavirenz; rifampin; pharmacogenetic
Categories
Ask authors/readers for more resources
In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
